Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.4B
138M shares
52-week range
$9.23 – $28.44
4% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
Borrow rate
0.42%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.73B | $3.87B | $4.09B | $4.14B | $4.45B | $4.66B | $4.37B | $4.25B |
| Cost of revenue | $2.90B | $2.44B | $2.59B | $2.72B | $3.00B | $2.98B | $2.83B | $2.76B |
| Gross profit | $1.83B | $1.43B | $1.49B | $1.42B | $1.46B | $1.68B | $1.54B | $1.49B |
| Gross margin | 38.7% | 37.0% | 36.6% | 34.2% | 32.7% | 36.1% | 35.3% | 35.1% |
| R&D | $218.6M | $119.2M | $121.7M | $122.0M | $123.1M | $122.5M | $112.2M | $95.4M |
| Operating income | $236.5M | $174.7M | $265.2M | $410.4M | $78.9M | $151.9M | $112.9M | $343.3M |
| EBITDA | $906.0M | $662.0M | $518.4M | $695.9M | $355.5M | $525.0M | $433.0M | −$797.9M |
| Net income | $131.0M | $146.1M | −$162.6M | −$68.9M | −$140.6M | −$12.7M | −$171.8M | −$1.43B |
| Net margin | 2.8% | 3.8% | -4.0% | -1.7% | -3.2% | -0.3% | -3.9% | -33.5% |
| EPS (diluted) | 0.95 | 1.07 | -1.19 | -0.98 | -0.97 | -0.09 | -1.25 | -10.29 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4.1B | $2.12 | $2.08–$2.16 | 3 |
| 2027 | $4.1B | $2.37 | $2.27–$2.46 | 3 |
| 2028 | $4.2B | $2.67 | $2.63–$2.73 | 1 |
| 2029 | $4.1B | $2.81 | $2.77–$2.86 | 1 |
Forward consensus · source: Financial Modeling Prep
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
www.perrigo.comNo one on the platform currently holds PRGO.
No tracked institution reports a position in PRGO as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-29 | $0.2900 | 2026-06-16 |
| 2026-03-02 | $0.2900 | 2026-03-24 |
| 2025-11-28 | $0.2900 | 2025-12-16 |
| 2025-08-29 | $0.2900 | 2025-09-16 |
| 2025-05-30 | $0.2900 | 2025-06-17 |
| 2025-03-07 | $0.2900 | 2025-03-25 |
| 2024-11-29 | $0.2760 | 2024-12-17 |
| 2024-08-30 | $0.2760 | 2024-09-17 |
| 2024-05-31 | $0.2760 | 2024-06-18 |
| 2024-03-07 | $0.2760 | 2024-03-26 |
No one on the platform has traded PRGO yet.
| $1.9B |
| — |
| HTFLHeartflow, Inc. Common Stock | $34.85 | -2.24% | $3.0B | — |
| LIVNLivaNova PLC | $83.06 | -0.44% | $4.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
| 2023-11-30 |
| $0.2730 |
| 2023-12-19 |
| 2023-08-31 | $0.2730 | 2023-09-19 |
Trading at 0.3× sales vs its 1.0× historical median P/S.
Fair value ≈ $31.23 · price $10.05 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$PRGO nope. I continue to DCA. My next add will be at $9.50 then $9.25. I think eventually overall market will correct and rotate some capital into beat up names that people actually need. Food stocks are at all time lows also. $CAG and $FLO I’m also accumulating.
View on StockTwits ↗$PRGO am i the only one who sees value in this name ?
View on StockTwits ↗$PRGO lowering the debt! Per current inflation level, debt cost would be too huge to bear?
View on StockTwits ↗$PRGO Cramer said he doesn't want Perrigo Company plc (NYSE:PRGO), adding that it's a “value trap” and doesn't have any growth
View on StockTwits ↗$PRGO Cramer said not to buy. Y'all know what that means..
View on StockTwits ↗$PRGO bullish for another run if we can close the week above 11.15
View on StockTwits ↗$PRGO past 3 trading days well above average volume today so far below average. I think this is a shakeout before move above $12.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.